Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies

Clin Drug Investig. 2021 Apr 23. doi: 10.1007/s40261-021-01024-7. Online ahead of print.


BACKGROUND: Solid tumors are a common predisposing factor for invasive candidiasis (IC) or candidemia due to IC.

OBJECTIVES: Post hoc analysis of patient-level efficacy and safety data from six studies of anidulafungin (with similar protocols/endpoints) in adults with IC/candidemia summarized by past or recent diagnosis of solid tumors.

PATIENTS/METHODS: Patients received a single intravenous (IV) dose of anidulafungin 200 mg, followed by 100 mg once daily. After ≥ 5 to ≥ 10 days of IV treatment, switch to oral voriconazole/fluconazole was permitted in all but one study. Time of solid tumor diagnosis was defined as past, ≥ 6; and recent, < 6 months prior to study entry. Primary endpoint: global response of success (GRS) rate at the end of IV therapy (EOIVT). Secondary endpoints included the GRS rate at the end of all therapy (EOT), all-cause mortality, and safety.

RESULTS: The GRS rate in the overall population was 73.4% at EOIVT and 65.5% at EOT. Past or recent solid tumor diagnosis did not affect GRS at EOIVT or EOT (past: 75.5% and 71.4%; recent: 72.2% and 62.2%, respectively). All-cause mortality was 14.4% on day 14 and 20.1% at day 28. Most treatment-emergent adverse events were mild/moderate in severity (81.6%).

CONCLUSIONS: Treatment of IC was effective regardless of the time of solid tumor diagnosis.

TRIAL REGISTRATION: Data were pooled from six studies: NCT00496197 (first posted on on July 4, 2007); NCT00548262 (first posted on on October 23, 2007); NCT00537329 (first posted on on October 1, 2007); NCT00689338 (first posted on on June 3, 2008); NCT00806351 (first posted on on December 10, 2008); NCT00805740 (first posted on on December 10, 2008).

PMID:33891293 | DOI:10.1007/s40261-021-01024-7